EFOMP policy statement 17: The role and competences of medical physicists and medical physics experts in the different stages of a medical device life cycle. Asten, Wim & Markidou, Erato & Gromoll, Christian & Gourzoulidis, George & Maguire, Susan & Guidi, Gabriele & Pace, Eric & Spruijt, Hugo & Martinez-Ortega, Jaime & Klöck, Stephan. (2022). Physica Medica. 104. S18. 10.1016/S1120-1797 (22) 02155-X. Ophthalmologie Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Munk MR, Somfai GM, de Smet MD, Donati G, Menke MN, Garweg JG, Ceklic L. The Int J Mol Sci. 2022 Jul 8;23(14):7585. doi: 10.3390/ijms23147585. PMID: 35886930; PMCID: PMC9319632. Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study. Bograd A, Fuchs D, Bächtiger J, Pfister IB, Spindler J, Hoogewoud F, Gugleta K, Böni C, Guex-Crosier Y, Garweg JG, Tappeiner C. Ocul Immunol Inflamm. 2022 May 19:1-8. doi: 10.1080/09273948.2022.2075761. Epub ahead of print. PMID: 35588311. Outer retinal features in OCT predict visual recovery after primary macula-involving retinal detachment repair. Hänsli C, Lavan S, Pfister IB, Schild C, Garweg JG. PLoS One. 2022 May 5;17(5):e0268028. doi: 10.1371/journal.pone.0268028. PMID: 35511781; PMCID: PMC9070941. Uveitisinduktion durch immunonkologische Therapien, speziell Checkpoint-Inhibitoren [Induction of Uveitis by Immune-Oncologic Therapies, Namely Checkpoint Inhibitors]. Garweg JG. Klin Monbl Augenheilkd. 2022 Apr;239(4):575-581. German. doi: 10.1055/a-1766-6119. Epub 2022 Apr 26. PMID: 35472809. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. Garweg JG, Štefanickova J, Hoyng C, Niesen T, Schmelter T, Leal S, Sivaprasad S; VIOLET Investigators. Adv Ther. 2022 Jun;39(6):2701-2716. doi: 10.1007/s12325-022-02119-z. Epub 2022 Apr 12. PMID: 35412227; PMCID: PMC9123040. Pathophysiological Considerations in Periorbital Necrotizing Fasciitis: A Case Report. Hadizamani Y, Anastasi S, Schori A, Lucas R, Garweg JG, Hamacher J. Ocul Immunol Inflamm. 2022 Apr 11:1-6. doi: 10.1080/09273948.2022.2032190. Epub ahead of print. PMID: 35404751. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, Wolf S, Gupta V, Ngah NF, Liew G, Tuli R, Tadayoni R, Dhoot D, Wang L, Bouillaud E, Wang Y, Kovacic L, Guerard N, Garweg JG. Am J Ophthalmol. 2022 Jun;238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14. PMID: 35038415. Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series. Garweg JG, Traine PG, Garweg RA, Wons J, Gerhardt C, Pfister IB. Eye (Lond). 2022 Apr;36(4):862-868. doi: 10.1038/s41433-021-01562-6. Epub 2021 May 3. PMID: 33941877; PMCID: PMC8956692. Aqueous Humor Apolipoprotein Concentration and Severity of Diabetic Retinopathy in Type 2 Diabetes. Saucedo L, Pfister IB, Schild C, Zandi S, Garweg JG. Mediators Inflamm. 2022 Nov 10;2022:2406322. doi: 10.1155/2022/2406322. PMID: 36405993; PMCID: PMC9671721. Effect of finerenone on the occurrence of vision-threatening complications in patients with non- proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR). Rossing P, Garweg JG, Anker SD, Osonoi T, Pitt B, Rosas SE, Ruilope LM, Zhu D, Brinker M, Finis D, Leal S, Schmelter T, Bakris G. Diabetes Obes Metab. 2022 Nov 4. doi: 10.1111/dom.14915. Epub ahead of print. PMID: 36331803. Long-Term Outcomes in Children with Congenital Toxoplasmosis – A Systematic Review. Garweg JG, Kieffer F, Mandelbrot L, Peyron F, Wallon M. Pathogens. 2022 Oct 15;11(10):1187. doi: 10.3390/pathogens11101187. PMID: 36297244; PMCID: PMC9610672. Diagnostik und Behandlung der okulären Toxoplasmose: Ergebnisse einer Umfrage Diagnostics and treatment of ocular toxoplasmosis: Results of a survey Taghavi-Eraghi A, Garweg JG, Pleyer U. Ophthalmologie. 2022 Jul 26. German. doi: 10.1007/s00347-022-01691-7. Epub ahead of print. PMID: 35925359. Functional Outcome After Macular Hole Surgery: Comparison of Standard Perimetry with Microperimetry. Wons J, Pfister IB, Anastasi S, Steinhauer S, Niderprim SA, Garweg JG. Clin Ophthalmol. 2022 Jul 11;16:2235-2243. doi: 10.2147/OPTH.S367431. PMID: 35844664; PMCID: PMC9286483. International Ocular Toxoplasmosis Study Group; Smith JR. Current practice in the management of ocular toxoplasmosis. Yogeswaran K, Furtado JM, Bodaghi B, Matthews JM; Br J Ophthalmol. 2022 Feb 23:bjophthalmol-2022-321091. doi: 10.1136/ bjophthalmol-2022-321091. Epub ahead of print. PMID: 35197262. Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series. Garweg JG, Traine PG, Garweg RA, Wons J, Gerhardt C, Pfister IB. Eye (Lond). 2022 Apr;36(4):862-868. doi: 10.1038/s41433-021-01562-6. Epub 2021 May 3. PMID: 33941877; PMCID: PMC8956692. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. Garweg JG, Štefanickova J, Hoyng C, Niesen T, Schmelter T, Leal S, Sivaprasad S; VIOLET Investigators. Adv Ther. 2022 Jun;39(6):2701-2716. doi: 10.1007/s12325-022-02119-z. Epub 2022 Apr 12. PMID: 35412227; PMCID: PMC9123040. Outer retinal features in OCT predict visual recovery after primary macula-involving retinal detachment repair. Hänsli C, Lavan S, Pfister IB, Schild C, Garweg JG. PLoS One. 2022 May 5;17(5):e0268028. doi: 10.1371/journal.pone.0268028. PMID: 35511781; PMCID: PMC9070941. 95 Geschäftsbericht 2022 Lindenhofgruppe Lehre und Forschung
RkJQdWJsaXNoZXIy MzQxOTE=